Multistage Vaccines For The Prevention Of Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$884,290.00
Summary
Almost two million people die from tuberculosis (TB) each year. The current vaccine, BCG, is ineffective at controlling TB and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with novel delivery strategies to develop new TB vaccines. We will also determine the type of immune response needed to protect against TB, which will aid progression of vaccines into clinical trials.
Pathogenic Consequences And Mechanistic Insights Of Daptomycin Resistance In Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$540,633.00
Summary
Staphylococcus aureus is one of the most common human bacterial pathogens. This project aims to characterise the mechanisms that Staph uses to develop resistance to one of our last-line antibiotics, and will determine the effects of this resistance on the ability of the bacteria to cause human disease.
Mycobacterial Control Of The Establishment And Outcome Of Infection
Funder
National Health and Medical Research Council
Funding Amount
$311,956.00
Summary
Tuberculosis (TB) claims almost two million lives every year. TB subverts host immunity by directing the immune cells to launch an ineffective response to infection. One such trick is to hijack control of a class of molecules called eicosanoids from the host. This project will use a validated zebrafish model of TB infection to pinpoint the mechanisms used by mycobacteria to subvert normal eicosanoid production. Findings from this work may to aid the creation of novel anti-TB therapies.
New Candidate Vaccines To Prevent Tuberculosis: Preclinical Assessment Of Efficacy, Safety And Mechanism Of Protection
Funder
National Health and Medical Research Council
Funding Amount
$594,133.00
Summary
Almost two million people die from tuberculosis (TB) each year. The curent vaccine, BCG, is ineffective at controlling TB and and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with our innovative vaccine technology to develop new vaccines to control TB. We will also try and understand why BCG is not effective, and use this information to further improve TB vaccination.
Antibiotic Resistance And Host Immune Evasion In Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$644,428.00
Summary
Staphylococcus aureus is one of the most common bacteria that infects humans. This project aims to characterise the mechanisms that Staph uses to develop resistance to one of our last-line antibiotics, and will determine the effects of this resistance on the ability of the bacteria to cause human disease. The work will also investigate new treatment strategies to tackle this challenging bacteria.
Infectious diseases plague mankind; with infections responsible for approximately 20% of all deaths worldwide. New strategies are urgently needed and we have positioned our research to address questions around how to forestall bacterial pathogens in the initial phases of invasion of human tissues and provide full understanding of the key molecules on the surfaces of bacterial cells. This fundamental knowledge is crucial to new drugs, vaccines and infection-resistant medical devices.
Role Of Hypoxia Inducible Factor In Innate Immune Function Against Gram-positive Pathogens
Funder
National Health and Medical Research Council
Funding Amount
$241,352.00
Summary
Our society is currently facing the rise of drug-resistant pathogens ("superbugs") such as the potentially devastating methicillin-resistant Staphylococcus aureus, or _MRSA�. Recently, a molecule known as HIF has been shown to control the ability of our white blood cells to kill bacteria. This proposal aims to investigate the use of HIF boosting drugs to treat infections. These novel HIF agonists could be used alongside conventional antibiotics to improve infectious disease.
Discovery Early Career Researcher Award - Grant ID: DE120101340
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Subversion of innate immune responses by pathogenic Escherichia coli. This project will determine how bacteria that cause diarrhoeal diseases prevent the immune system from signalling efficiently. It will provide important information not only about how the bacteria establish disease, but also provide insight into the host response in the early stages of infection.
Iron, Pseudomonas Aeruginosa And Lung Disease In Cystic Fibrosis.
Funder
National Health and Medical Research Council
Funding Amount
$322,875.00
Summary
Cystic fibrosis (CF) is the most common lethal geneticdisease in Caucasians. The worldwide incidence of the disorder is approximately 1 in 2,500 live births. The most significant clinical manifestation of CF is chronic lung infection, particularly with the bacterium, Pseudomonas aeruginosa. Even with the current aggressive antibiotic treatment regimens most patients ultimately succumb to infection with this organism and die before they reach 40 years-of-age. The overall aim of our work is to inc ....Cystic fibrosis (CF) is the most common lethal geneticdisease in Caucasians. The worldwide incidence of the disorder is approximately 1 in 2,500 live births. The most significant clinical manifestation of CF is chronic lung infection, particularly with the bacterium, Pseudomonas aeruginosa. Even with the current aggressive antibiotic treatment regimens most patients ultimately succumb to infection with this organism and die before they reach 40 years-of-age. The overall aim of our work is to increase the understanding of how P. aeruginosa persists in the CF lung, with the goal of developing more effective therapeutic strategies to eliminate chronic infection with this bacterium. The new perception is that P. aeruginosa bacteria flourish in mucus with a low oxygen content within the CF lung and persist despite aggressive antibiotic therapy because they have adopted an antibiotic-resistant, biofilm mode of growth. This has opened up exciting directions for new therapeutic strategies. Factors in CF mucus that regulate this mode of bacterial growth are potential targets for intervention. Our past work has shown that iron is likely to be one such factor. In this study, we will extend these findings and determine whether using iron-binding chemicals can disrupt these biofims and allow the host immune system and antibiotics to work more efficiently to kill the bacteria. Not only will this study provide further insights into the pathogenesis of P. aeruginosa in CF and the role of iron, but ultimately it will contribute to the improved treatment and prevention of chronic infection with this organism.Read moreRead less
Understanding The Complex Relationship Between Host, Pathogen And Antibiotic Factors On Treatment Outcome In Serious Bacterial Infections
Funder
National Health and Medical Research Council
Funding Amount
$380,945.00
Summary
Millions of people still die every year from bacterial infections despite the availability of antibiotics. The same bacterial infection in one person can behave very differently in another person, so infections can range from trivial to life-threatening or fatal. Understanding the relationship between the patient, the infecting bacteria and the antibiotic treatment given will ultimately help to predict and improve outcomes for patients with serious bacterial infections.